ClinicalTrials.gg
RecruitingNCT05118633Updated Jun 2, 2026

Technology Assisted Treatment for Trichotillomania

An interventional study of Keen2 bracelet and Reminder bracelet in Trichotillomania, sponsored by HabitAware Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by HabitAware Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Trichotillomania with a site in United States — 5 open to participants now, 7 under way, 1 of them phase 3. Trichotillomania · United States.

Planned enrollment
6th of 37
90 · median 39
Started
2026
with 1 other
No phase
18 of 39
3 open now
Registered
33rd of 39
by date
Lead sponsor
3 of 39
HabitAware Inc.

Among the 39 studies in Trichotillomania with a site in United States, this one is the 6th largest by planned enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2026, is one of 18 with no phase, and was the 33rd registered.

Trichotillomania

48 studies on the registry are indexed under Trichotillomania; 8 are open to participants now.

Browse Trichotillomania studies →

Open to participants now

5 of the 39 studies in Trichotillomania with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Trichotillomania studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Trichotillomania with a site in United States, or all of them as a file.
02

Study summary

The investigators are testing two digital health interventions for trichotillomania (TTM), via a randomized trial design.

Read the detailed description

Trichotillomania is characterized by recurrent hair pulling despite repeated attempts to stop, resulting in hair loss as well as significant distress and impairment. Behavior therapies focused on increasing awareness of hair pulling followed by the use of an incompatible behavior (i.e., competing response) and other behavioral strategies (e.g., stimulus control) are efficacious. In this randomized control trial, we are testing the preliminary efficacy of two digital health interventions for adults with TTM (N=90). Participants will be randomly assigned (50/50 chance) to receive 8 weeks of (a) a digital behavior therapy that includes a wrist worn motion detection device to enhance awareness and a companion mobile application that provides psychoeducation, awareness training (e.g., self-monitoring), and behavioral strategy suggestions or (b) a digital general wellness intervention that includes a reminder bracelet (i.e., a wrist-worn visual reminder not to pull) accompanied by a smartphone app that includes general context logging and delivery of general health tips.

03

Conditions studied

  • Trichotillomania

Browse trials for

Keywords

  • Hair Pulling Disorder
  • Body-Focused Repetitive Behaviors
  • Trichotillomania
  • habit reversal training
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years of age or older (criterion 1a) with a diagnosis of TTM focused on primary hair pulling location(s) above the neck (e.g., scalp, eyebrows, eye lashes, beard) (criterion 1b).
  2. English language fluency (criterion 2).
  3. Report no current pharmacological intervention targeting TTM symptoms OR a 6-week course of the intervention without change in dosage and intent for that dosage to remain stable for the 12 weeks of this trial (criterion 3a).
  4. Report no current psychosocial intervention targeting TTM (criterion 3b)

4. Reliable and consistent access to the internet and/or mobile device permitting the participant to meet with someone virtually for 90 min.

5. Owns a mobile phone running on Apple's operating system (iOS 6+) 6. Identifies a support person that is able to be contacted if an emergency arises.

Exclusion criteria

Exclusion Criteria:

  1. Current suicidal/homicidal ideation, intent, or plan (criterion 1a) or a diagnosis of another psychiatric condition that may impede a participant's ability to fully utilize the app (e.g., psychotic disorder, eating disorder, moderate to severe major depressive disorder [defined by meeting diagnostic criteria on the MINI and a score >13 on DASS-21]) (criterion 1b)
  2. Has not used HabitAware's Keen or Keen2 bracelet in the past 24 months.
  3. Residing outside the United States
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Keen2 bracelet and app

    8-week intervention involving a wrist-worn motion detection device (Keen2 bracelet) and accompanying smartphone app that delivers components of behavior therapy for TTM.

    Device: Keen2 bracelet · Behavioral: Keen2 app

  • Placebo comparator
    Reminder bracelet and health tips app

    8-week intervention involving a wrist-worn reminder device (non-vibrating bracelet) and accompanying smartphone app that prompts for general context logging and delivers general health tips.

    Device: Reminder bracelet · Behavioral: Health Reminders App

Interventions

  • DeviceKeen2 bracelet

    Participants will receive an awareness bracelet (Keen2) which vibrates upon detection of hair pulling motion, supporting behavior therapy for hair pulling delivered by the Keen2 app.

  • DeviceReminder bracelet

    Participants will receive a non-vibrating bracelet to wear as a visual reminder not to pull.

  • BehavioralKeen2 app

    Participants will be given access to a smartphone app. The bracelet and app work together to implement key features of habit reversal training for TTM, including psychoeducation, awareness training, competing response training, and personalized just-in-time stimulus control and other behavioral strategy reminders.

  • BehavioralHealth Reminders App

    Participants will be given access to a smartphone app that will prompt them to log their context (e.g., location and activity) throughout the day and provide general health tips.

06

What researchers measure

Primary outcomes

  1. Clinician-rated trichotillomania (TTM) symptom severity at endpoint (week 8)

    Scores on the NIMH Trichotilomania Severity Scale (NIMH-TSS), a clinician-administered assessment of TTM symptom severity, will be compared across conditions at endpoint (week 8), controlling for baseline severity. The NIMH-TSS is a 5-item clinician rated measure of TTM severity ranging from 0-25, with higher scores indicating more severe symptoms.

    Time frame: Eight weeks

Secondary outcomes

  1. Self-reported trichotillomania (TTM) severity at endpoint (week 8)

    Scores on the Massachusetts General Hospital Hair Pulling Scale (MGH-HS), a validated and widely used 7-item Likert self-report measure of TTM symptom severity, will be compared across conditions at endpoint (week 8), controlling for baseline severity. MGH-HS scores range from 0 to 28, with higher scores corresponding with more severe TTM symptoms.

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2021
First posted
Nov 12, 2021
StartActual
May 15, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05118633
Lead sponsor
HabitAware Inc.
Collaborators
Kent State University
Responsible party
Sponsor
First posted
Nov 12, 2021
Start date
May 15, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 2, 2026

Study contacts

Sameer Kumar, BS
Contact
sameer@habitaware.com
248-990-4720

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion